Evaluating the potential for immune escape: how likely is an antibody to protect against a specific SARS-CoV-2 variant?
Author(s): Sandra Porter1, Uwe Hilgert2, Erica Lannan3, Michelle Stieber4
1. Digital World Biology 2. Bio5 Institute 3. Prairie State College 4. Cerritos College
1778 total view(s), 1460 download(s)
Summary:
Commercial antibodies to the SARS-CoV-2 spike protein have been successfully used to treat people with COVID-19. Unfortunately, as the SARS-CoV-2 virus evolves, new variants have appeared that can escape some of these antibodies. In fact, many…
Contents:
- CDC info 5_3_2022.xlsx(XLSX | 12 KB)
- Commercial Anti-SARS Antibodies.xlsx(XLSX | 15 KB)
- Instructor Guide Antibody protection against SARS-CoV-2.docx(DOCX | 22 KB)
- Intro Student Antibody protection against SARS-CoV-2.docx(DOCX | 20 KB)
- Part_1 Changing shape data.docx(DOCX | 26 KB)
- Part_1 Changing shape SARs-CoV-2 spike.docx(DOCX | 867 KB)
- Part_2 Finding aligning data.docx(DOCX | 28 KB)
- Part_2 Finding aligning structures.docx(DOCX | 1 MB)
- Part_3 Amino acid contacts data.docx(DOCX | 27 KB)
- Part_3 Amino acid contacts.docx(DOCX | 605 KB)
- Part_4 NextStrain.docx(DOCX | 3 MB)
- Part_4 NextStrain_data.docx(DOCX | 29 KB)
- Part_5 Predict effects data.docx(DOCX | 96 KB)
- Part_5 Predict effects of spike mutations.docx(DOCX | 2 MB)
- https://NextStrain.org
- National Center for Biotechnology Information
- SARS CoV 2 variants vs Antibodies - YouTube
- iCn3D: Web-based 3D Structure Viewer
- SARS-CoV-2 Abs vs Variants Feb2022.pptx(PPTX | 18 MB)
- License terms
Comments
There are no comments on this resource.